Navigation Links
BioInformatics, LLC New Market Report - Next Generation Sequencing
Date:10/18/2011

ARLINGTON, Va., Oct. 18, 2011 /PRNewswire/ -- BioInformatics, LLC announces the release of their newest market report:

The Global Outlook for Next Generation Sequencing:  Usage, Preferences and Budgets (11-003)

This worldwide study of the academic and pharma/biotech sectors provides a market analysis of next generation sequencing (NGS) and an assessment of the brand equity and brand positioning of companies providing NGS instrumentation and consumables.  To better understand the current market for NGS technologies, the report includes an in-depth exploration of NGS technologies currently deployed, workflow and types of applications.  

The following suppliers' products were provided as some of the answer choices in the survey:

Agilent Technologies
Fluidigm
Helicos Biosciences
Idaho Technology, Inc.
Illumina
Invitrogen (Life Technologies)
Ion Torrent (Life Technologies)
Life Technologies/SOLiD Sequencing
NuGEN
Pacific Biosciences
RainDance Technologies
Roche/NimbleGen

"Beyond the traditional sampling of genome content, a diversity of applications are emerging for next generation sequencing technologies, firmly securing its place at the forefront of scientific discovery," states Tamara Zemlo, Ph.D., MPH, Vice President of Advisory Services.  Dr. Zemlo adds that: "The market analysis presented in this report will provide life science suppliers with the guidance they need to keep up with such a rapidly advancing field."

To learn more about this report, a complimentary Executive Summary is available at:
http://www.gene2drug.com/index.php?page=reports&id=220

ABOUT BIOINFORMATICS, LLC

BioInformatics, LLC is the premier research and advisory firm serving the life science industry.  By leveraging our professional social network of more than 66,000 life scientists, we have supported more than 500 companies and provided insights that lead to better business decisions.  Our assignments include assessing the size and attractiveness of markets, optimizing product configurations and pricing, validating corporate acquisitions, measuring customer loyalty, and evaluating brand strength and positioning.

For more information contact:

Mary Follin
Manager, Marketing/Sales
BioInformatics, LLC
2111 Wilson Blvd., Suite 250
Arlington, VA  22201
703.778.3080 x13 (phone)
m.follin@gene2drug.com

http://www.gene2drug.com/


'/>"/>
SOURCE BioInformatics, LLC
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. BioInformatics, LLC Offers Solutions for Optimizing Service and/or Maintenance Contracts
2. BioInformatics, LLC Studies Effective Strategies for Scientific Publishing in a Web 2.0 World
3. BioInformatics, LLC New Report -- The Market for Antibodies: Keys to Success for Commercial Suppliers, Vol. III
4. BioInformatics, LLC New Report - The Market Outlook for Research Products in FY2010
5. BioInformatics, LLC New Market Report - Genomics Technologies
6. BioInformatics, LLC New Market Report - Membrane Protein Structure
7. Concentric Medical(R) Announces Co-Marketing Agreement With InTouch Health(R) to Advance Acute Ischemic Stroke Care
8. XTL Biopharmaceuticals Receives Notice of Non-Compliance with Nasdaq Marketplace Rule Due to Changes in Board Composition
9. BMP Sunstone Receives Production License from the SFDA to Manufacture and Market Pediatric Multivitamin Granules in the PRC
10. Huifeng Bio-Pharmaceutical (HFGB) to Attend CPhI South America 2008 Pharmaceutical Conference; The First CPhI Conference to be held in the Emerging Market of Brazil
11. Oncothyreon announces receipt of notice of non-compliance with market value of listed securities standard for listing on The NASDAQ Global Market
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/24/2017)... ... 24, 2017 , ... Delpor, Inc. (Delpor), a biotechnology company focused on drug ... Mental Health (NIMH) for the further advancement of the company’s 3-month olanzapine product ( ... expected to deliver therapeutic levels of olanzapine for a period of 3 months., “We ...
(Date:2/24/2017)... , Feb. 24, 2017 Provectus Biopharmaceuticals, ... the "Company"), a clinical-stage oncology and dermatology biopharmaceutical ... deadline to participate in its previously announced rights ... of shares of common stock and Series C ... of listed warrants. As previously ...
(Date:2/24/2017)... 2017 Symic Bio, a biopharmaceutical company focused ... of therapeutics, announced today the completion of enrollment for ... disease. The trial will evaluate the safety and efficacy ... reduction of restenosis following angioplasty. "We,re ... SB-030," said Nathan Bachtell , M.D., Chief Medical ...
(Date:2/24/2017)... Cord Blood Corporation (NYSE: CO ) ("CCBC" ... collection, laboratory testing, hematopoietic stem cell processing and stem ... for the third quarter and first nine months of ... Third Quarter of Fiscal 2017 Highlights ... by 18.6% to RMB200.9 million ($28.9 million). ...
Breaking Biology Technology:
(Date:2/8/2017)... NEW YORK , Feb. 7, 2017 Report ... ... and should reach $11.4 billion by 2021, growing at a ... Report Includes - An overview of the global markets for ... from 2015, estimates for 2016, and projections of compound annual ...
(Date:2/7/2017)... 2017   MedNet Solutions , an innovative SaaS-based ... clinical research, is pleased to announce that the latest ... highly flexible and award winning eClinical solution, is now ... is a proven Software-as-a-Service (SaaS) clinical research technology ... but also delivers an entire suite of eClinical tools ...
(Date:2/6/2017)... According to Acuity Market Intelligence, ongoing ... to continue to embrace biometric and digital identification ... Border Control (ABC) eGates and 1436 Automated Passport ... 163 ports of entry across the globe. Deployments ... combined CAGR of 37%. APC Kiosks reached 75% ...
Breaking Biology News(10 mins):